Clinical Phase Equipment & Supplies
170 equipment items found
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
Gesynta Pharma’s drug candidate GS-073 is expected to enter clinical phase I in 2022. It is currently in the final stages of preclinical development. This project will be addressing an indication with high unmet need, which is separate from systemic ...
Manufactured by:BCN Peptides S.A. based inSant Quintí de Mediona, SPAIN
BCN Peptides ensures the highest qualities and shortest times thanks to our experience in the manufacturing of peptides for all clinical phases, from pre-clinical to phase I, II, III and commercial stage. Our facility has been specially designed by BCN Peptides applying our expert know-how in Solid Phase Peptide ...
Manufactured by:RapiGEN Inc. based inSuwon-si, SOUTH KOREA
NS1 (non-structural protein 1) is a highly conserved glycoprotein that is essential for the viability of the Dengue virus and is produced both in membrane-associated and secretory forms by the virus. NS1 antigen is present at a high concentration in the blood of dengue virus-infected patients during the early clinical phase of the ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Using a revolutionary form of living biotherapy targeting the lung, YSOPIA is pioneering the innovative field of the lung microbiome. As part of this program, YSOPIA has selected a clinical candidate having demonstrated strong in vivo efficacy on inflammation and lung functions. We have achieved the formulation feasibility and cleared the regulatory hurdles associated with ...
Manufactured by:Virometix AG based inSchlieren, SWITZERLAND
With V-306 Virometix offers a differentiated approach to RSV vaccine development. Our vaccine candidate – already in clinical phase I – demonstrates strong, durable, specific and protective immune responses, with minimal risk of vaccine-associated enhanced respiratory disease ...
Manufactured by:CanaQuest Medical Corp. based inMississauga, ONTARIO (CANADA)
Clinical testing on humans can only begin after a pre-clinical phase, involving laboratory studies (in vitro) and tests on animals, which has shown that the experimental drug is considered safe and effective. However, no animal is sufficiently similar to humans (even genetically modified ones) to make human testing unnecessary. ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our partner, Indivior, has licensed worldwide rights to our GABAB PAM program and is responsible for all development, manufacture and commercialization of any selected GABAB PAM drug candidates. Under the agreement, we are responsible for executing a research program funded by Indivior to discover novel drug candidates. Indivior has the right to select GABAB PAM drug candidates from our research ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
We are developing muscarinic acetylcholine receptor subtype 4 positive allosteric modulator, or M4 PAM, as a novel orally available treatment for schizophrenia & other psychosis. Schizophrenia affects approximately 24 million people worldwide, requiring lifelong treatment to reduce severe impact on their everyday life. The market for antipsychotics represents over $7B annual sales in the ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
It is potentially indicated for the treatment of postmenopausal women with OP at high risk for fracture. First subject has been doesd in the international multi-centre phase 3 clinical trial in China for the treatment of postmenopausal osteoporosis in women with high fracture ...
Manufactured by:Poietis based inPessac, FRANCE
NGB-C is a clinical-grade, GMP-compliant Bioprinter designed to meet the needs of Advanced Therapy Medicinal Products (ATMP) production and the requirements of Poietis’ ...
by:Palvella Therapeutics. based inWayne, PENNSYLVANIA (USA)
QTORIN™ rapamycin 3.9% is a novel targeted topical therapy being studied for Microcystic Lymphatic Malformations (Micro LM). Palvella is enrolling a phase 2 clinical study for people with Micro ...
by:Horizon Therapeutics plc based inSaint Kevin`s, IRELAND
We are investigating daxdilimab in dermatomyositis, discoid lupus erythematosus and lupus nephritis as well conducting Phase 2 clinical trials in alopecia areata and systemic lupus ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
Infigratinib is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven cancers. Multiple Phase 3 clinical trials are currently enrolling; please explore www.clinicaltrials.gov for more information. TRUSELTIQ™ (infigratinib) obtained accelerated approval by FDA, was conditionally approved by ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX04-O, recombinant anti-VEGF humanised monoclonal antibody injection. It is indicated for wet age-related macular degeneration (wAMD). HLX04-O was granted Phase 3 clinical study approvals in Australia, the United States, Singapore and the EU countries such as Latvia, Hungary and Spanish. In April 2022, the first patient in Australia and Latvia was dosed in the ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX07, recombinant anti-epidermal growth factor receptor (EGFR) humanised monoclonal antibody injection independently researched and developed as biobetter. It was granted IND approvals to be evaluated in clinical trials in China and the United States. It demonstrated favorable safety and tolerability profile in a prospective, open-label, dose-escalation Phase 1 ...
Manufactured by:Vedanta Biosciences, Inc based inCambridge, MASSACHUSETTS (USA)
VE303 is an orally administered, rationally-defined bacterial consortium candidate being developed for high-risk Clostridioides difficile (CDI) infection. VE303 consists of 8 types of clonal human commensal bacteria strains selected for their ability to provide colonization resistance to C. difficile and manufactured under cGMP conditions. It is produced under cGMP conditions from pure, clonal ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
These indications have been validated with baclofen, an orthosteric agonist of GABAB and present a significant unmet medical need and commercial opportunity. We are in clinical candidate selection phase and expect IND enabling studies to be initiated in ...
Manufactured by:ViruSure GmbH based inVienna, AUSTRIA
Recombinant proteins are proteins expressed in cell lines which have been genetically modified by DNA recombinant technology. These therapeutics include recombinant blood clotting factors, hormones, enzymes, interferons, growth factors and other bioengineered ...
by:Starton Therapeutics based inParamus, NEW JERSEY (USA)
STAR-OLZ is a 5-day transdermal patch in development for the treatment of chemotherapy induced nausea and vomiting (CINV). STAR-OLZ successfully completed Phase 1 human bioavailability studies and is now preparing to advance to a Phase 2 clinical trial. Starton Therapeutics Phase 2 TROPIC-I clinical study will be ...
Manufactured by:Histocell based inDerio, SPAIN
ASC pre-differentiated to osteoblasts in Histobone scaffold (engineered synthetic bone substitute) for the treatment of bone defects caused by pseudoarthrosis, infections, resections, ...